BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL
Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]
National research team targets glioblastoma
MAY 31, 2019 — Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is due in part to limited early detection methods and an absence of effective treatment options. Funding […]
About Glioblastoma (GBM)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect […]
